15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Sabre Corpo, 0 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $1.50 to $1.50, so the covering firms are broadly aligned. The average target of $1.50 sits 21% below the current $1.89. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.01 next quarter toward $0.14 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Hold
Strong Buy00%
Buy00%
Hold1100%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Sabre Corpo.
As of Jul, 0 of 1 firms rate SABR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SABR EPS & revenue forecast
EPS · NEXT QUARTER
$0.01
Range $-0.02 – $0.04 · 2 analysts · -200% YoY
Next period, 2 analysts expect Sabre Corpo to earn $0.01 a share (range $-0.02 – $0.04), versus $-0.01 a year earlier. Full-year consensus is $0.01, growing to $0.14 the year after.
REVENUE · NEXT QUARTER
$734.1M
Range $728.7M – $744.5M · 2 analysts · +3% YoY
Revenue is expected to reach $734.1M (range $728.7M – $744.5M), +2.6% year-over-year. Full-year consensus is $2.9B, rising to $3.0B next year.
Top analysts covering Sabre Corpo
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SABR.
#1
Deepak Mathivanan
Cantor Fitzgerald · Rank #209
Hold
$4.00+111.6% to target
Overall win rate
36%
+ Follow
#2
AI
Alex Irving
Bernstein
Hold
$1.50-20.6% to target
Coverage
—
+ Follow
#3
Jed Kelly
Oppenheimer
Hold
No targeton SABR
Coverage
—
+ Follow
#4
Josh Baer
Morgan Stanley
Hold
$3.50+85.2% to target
Coverage
—
+ Follow
#5
VC
Victor Cheng
B of A Securities
Buy
$6.10+222.8% to target
Coverage
—
+ Follow
SABR stock forecast FAQ
What is SABR's average 12-month price target?+
The 1 analysts with a live target average $1.50 for Sabre Corpo over the next 12 months, ranging from a $1.50 high to a $1.50 low.
Is SABR stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 1 analyst ratings, 0 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover SABR?+
1 analysts have an active rating on Sabre Corpo, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering SABR?+
Among analysts who currently cover SABR, Deepak Mathivanan of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #209). Their current call is Hold with a $4.00 target.
What is Sabre Corpo's projected EPS for next quarter?+
The consensus estimate is $0.01 per share (range $-0.02 – $0.04) across 2 analysts. Full-year EPS is projected at $0.01, rising to $0.14 the following year.
How much revenue is Sabre Corpo expected to report next quarter?+
Consensus revenue is $734.1M (range $728.7M – $744.5M). Full-year revenue is projected at $2.9B, growing to $3.0B next year.
Have analysts been upgrading or downgrading SABR lately?+
As of Jul, 0 of 1 firms rate SABR a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SABR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
